A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical
study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to
previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173
subjects are expected to be enrolled in a single arm with the administration of Radotinib
400mg twice daily, which includes 10% of dropout rate.